Stock report · Delisted · Nasdaq
Blueprint Medicines Corp (BPMC)
129.28USD Delisted Final close · Jul 16, 2025
BPMC no longer trades. Blueprint Medicines was acquired by Sanofi on July 18, 2025.
All prices on this page are historical. The last trade was on July 16, 2025, at $129.28.
BPMC stock price history
Final trading statistics
- Final close
- $129.28
- Final trading day
- Jul 16, 2025
- Market cap at delisting
- $8.35B
- Shares outstanding
- 64.58M
- Final 52-week range
- $73.04 – $129.65
- Avg. volume (final 3 mo.)
- 3,727,505
- All-time high
- $129.36 · Jul 2025
- All-time low
- $13.34 · Feb 2016
- Return since IPO
- +585.1%
- Beta
- 0.83
- Book value / share
- $5.30
- Price / book
- 24.40
About Blueprint Medicines Corp
Blueprint Medicines Corporation was a precision therapy company developing drugs for genomically defined cancers and blood disorders in the U.S. and abroad. Its programs included AYVAKIT for systemic mastocytosis (SM) and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent SM and other mast cell disorders.
It was also developing GAVRETO for RET fusion-positive lung cancer and thyroid cancers, BLU-945 and BLU-451 for EGFR-driven non-small cell lung cancer, BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for advanced cancers. Partners included Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, Hoffmann-La Roche and Zai Lab.
Known as Hoyle Pharmaceuticals, Inc. until June 2011, the company was incorporated in 2008 and based in Cambridge, Massachusetts. Sanofi acquired it on July 18, 2025, paying $129.00 in cash per BPMC share plus a contingent value right worth up to $6.00; the last trade was on July 16, 2025 at $129.28.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA
- Employees
- 682
- IPO date
- April 30, 2015
- Delisted
- July 18, 2025
- SEC CIK
- 1597264
Blueprint Medicines financials before the delisting
The last 5 fiscal years Blueprint Medicines reported as a public company, fiscal year ending December.
BPMC revenue and net income
BPMC earnings per share
BPMC annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $508.82M | −$67.1M | −$1.08 |
| FY2023 | $249.38M | −$507.0M | −$8.36 |
| FY2022 | $204.04M | −$557.5M | −$9.35 |
| FY2021 | $180.08M | −$644.1M | −$10.92 |
| FY2020 | $793.74M | $313.9M | $5.24 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Blueprint Medicines stock FAQ
What happened to Blueprint Medicines stock?
Blueprint Medicines was acquired by Sanofi on July 18, 2025. The final close was $129.28 on July 16, 2025.
What did Blueprint Medicines shareholders receive?
Each BPMC share was converted into $129.00 in cash plus a contingent value right of up to $6.00. The deal was valued at up to about $9.5 billion.
Can I still buy BPMC stock?
No. BPMC is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on July 18, 2025.
What was the last price of BPMC?
BPMC last closed at $129.28 on July 16, 2025, which valued the company at about $8.35B.
How did Blueprint Medicines do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Blueprint Medicines reported revenue of $508.82M and net income of −$67.1M.
When did Blueprint Medicines go public?
Blueprint Medicines shares started trading on April 30, 2015.
BPMC no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.